CareDx, Inc. — Company profile
Healthcare · Diagnostics & Research · United States
Last price 71.52 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.70B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Details
| Name | CareDx, Inc. |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 765 |
| Founded | 1998 |
| Ipo Date | 2014-07-17 |
| Ceo | John Hanna |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US14167L1035 |
| Cusip | 14167L103 |
| Cik | 0001217234 |
| Sic | 8071 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| John Walter Hanna Jr. | President, Chief Executive Officer and Director |
| Keith S. Kennedy C.F.A., CPA | Chief Financial Officer and Chief Operating Officer |
| Jeffrey A. Novack | General Counsel and Secretary |
| Jessica Meng | Chief Commercial Officer |
| Kashif Rathore | Chief Technology Officer |
| Dr. Robert N. Woodward Ph.D. | Chief Scientific Officer |
| Nina D. Deka | Head of Investor Relations |
| Natasha Moshirian Wagner | Vice President of Corporate Communications |
| Marica Grskovic Ph.D. | Chief Strategy Officer |
| Jing Huang Ph.D. | Chief Data and Artificial Intelligence Officer |
Contact
| Address | 8000 Marina Boulevard, Brisbane, California 94005, United States |
| Phone | 415 287 2300 |
| Website | https://caredx.com |